NNC0519-0130 vs ribupatide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
NNC0519-0130
Developed by Novo Nordisk
NCT06326060 · Phase 2 · completed
The study was randomized and quadruple-blind, included placebo and active-comparator arms, and enrolled 354 participants; its primary endpoint was the clinical measure of relative body-weight change. Because the registry does not report whether this endpoint was met, the findings cannot currently support the highest evidence grade.
No aligned efficacy figure on record for this race.
ribupatide
Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals
NCT06396429 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 567 participants. The sponsor reports weight loss of up to 17.7% with ribupatide, 16.3 percentage points more than placebo, with up to 88.0% of treated participants losing at least 5% of body weight, and describes the trial as positive.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06974851 (registry estimate)
Reported efficacy
Percentage change from baseline in weight after 48 weeks of treatment (Baseline, Week 48); Proportion of subjects with weight loss of≥5% from baseline after 48 weeks of treatment (Week 48): Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss (met)
Result source: NCT06396429
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | NNC0519-0130 | ribupatide |
|---|---|---|
| Body weight, % change | —Not reported | —Not posted · NCT06396429 |
| Weight loss of 5% or more | —Not reported | —Not posted · NCT06396429 |
| Weight loss of 10% or more | —Not reported | —Not posted · NCT06396429 |
| Waist circumference, change (cm) | —Not reported | —Not posted · NCT06396429 |
Body weight, % change
- NNC0519-0130
- —Not reported
- ribupatide
- —Not posted · NCT06396429
Weight loss of 5% or more
- NNC0519-0130
- —Not reported
- ribupatide
- —Not posted · NCT06396429
Weight loss of 10% or more
- NNC0519-0130
- —Not reported
- ribupatide
- —Not posted · NCT06396429
Waist circumference, change (cm)
- NNC0519-0130
- —Not reported
- ribupatide
- —Not posted · NCT06396429
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
NNC0519-0130: no structured comparison results are available for Obesity.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ribupatide
Type 2 Diabetes
Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline
NNC0519-0130
Developed by Novo Nordisk
NCT05363774 · Phase 1 · completed
This was a randomized, blinded, placebo-controlled study, a genuine controlled design, but it measured only safety and drug levels rather than a clinical efficacy outcome, and results have not been posted yet, so the evidence reflects the design only. Its registered primary outcome on ClinicalTrials.gov is "Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) part" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
ribupatide
Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals
NCT06649344 · Phase 3 · completed
This phase 3 trial randomly assigned 884 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor, to once-weekly ribupatide 4 mg, ribupatide 2 mg or semaglutide 1 mg, with open-label treatment. The primary measure was HbA1c change at week 36, tested for non-inferiority against semaglutide. The company reports that both doses were non-inferior (HbA1c -2.78% and -2.34% against -2.29%) and that 4 mg was statistically superior, so the result is met. The margin and confidence intervals were not published, and the figures come from the company's own release.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07060456 (registry estimate)
Reported efficacy
Change in HbA1c (from baseline to 36 weeks treatment): Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo (met)
Result source: NCT06650007
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | NNC0519-0130 | ribupatide |
|---|---|---|
| HbA1c, change | —Not reported | —Not posted · NCT06650007 |
| Body weight, change (kg) | —Not reported | —Not posted · NCT06650007 |
| HbA1c below 7% | —Not reported | —Not posted · NCT06650007 |
| Fasting plasma glucose, change | —Not reported | —Not posted · NCT06650007 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT06650007 |
HbA1c, change
- NNC0519-0130
- —Not reported
- ribupatide
- —Not posted · NCT06650007
Body weight, change (kg)
- NNC0519-0130
- —Not reported
- ribupatide
- —Not posted · NCT06650007
HbA1c below 7%
- NNC0519-0130
- —Not reported
- ribupatide
- —Not posted · NCT06650007
Fasting plasma glucose, change
- NNC0519-0130
- —Not reported
- ribupatide
- —Not posted · NCT06650007
3-point MACE (% with event)
- NNC0519-0130
- —Not reported
- ribupatide
- —Not posted · NCT06650007
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
NNC0519-0130: no structured comparison results are available for Type 2 Diabetes.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNC0519-0130's landscape · ribupatide's landscape